title: Safety of serial monthly administration of triple-dose gadopentetate dimeglumine in multiple sclerosis patients: preliminary results of the BECOME trial.
authors.forename: Leo J
authors.initials: LJ
authors.lastname: Wolansky
authors.forename: Mohammad H
authors.initials: MH
authors.lastname: Haghighi
authors.forename: Evangelia
authors.initials: E
authors.lastname: Sevdalis
authors.forename: Stuart D
authors.initials: SD
authors.lastname: Cook
authors.forename: Nilay
authors.initials: N
authors.lastname: Sethi
authors.forename: Jiang
authors.initials: J
authors.lastname: Liu
authors.forename: George
authors.initials: G
authors.lastname: Joseph
authors.forename: Kimberly
authors.initials: K
authors.lastname: Tulloch
authors.forename: Diego
authors.initials: D
authors.lastname: Cadavid
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D003287:Contrast Media / Q000008:administration & dosage* / Q000009:adverse effects; D004334:Drug Administration Schedule; D019786:Gadolinium DTPA / Q000008:administration & dosage* / Q000009:adverse effects; D000068717:Glatiramer Acetate; D006801:Humans; D000068576:Interferon beta-1b; D016899:Interferon-beta / Q000627:therapeutic use; D008279:Magnetic Resonance Imaging; D009103:Multiple Sclerosis / Q000188:drug therapy / Q000473:pathology*; D010455:Peptides / Q000627:therapeutic use; D012449:Safety
chemical_list: D000276:Adjuvants, Immunologic; D003287:Contrast Media; D010455:Peptides; D000068576:Interferon beta-1b; D000068717:Glatiramer Acetate; D016899:Interferon-beta; D019786:Gadolinium DTPA